Phase3 trial comparing oral S-1 plus carboplatin with paclitaxel plus carboplatin in chemotherapy-naive patients with advanced non-small-cell lung cancer LETS Biomarker study

Phase3 trial comparing oral S-1 plus carboplatin with paclitaxel plus carboplatin in chemotherapy-naive patients with advanced non-small-cell lung cancer LETS Biomarker study - LETS Biomarker study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000006122

Enrollment

300

Registered

2011-08-05

Start date

2011-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Previously untreated stage IIIB/IV NSCLC

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients enrolled onto LETS study who had available tumor tissue specimens

Exclusion criteria

Exclusion criteria: Nothing particular

Design outcomes

Primary

Measure	Time frame
Protein and gene expression analysis Somatic mutation analysis Gene amplification analysis	—

Countries

Japan

Contacts

Public ContactShinichiro Nakamura

West Japan Oncology Group datacenter

datacenter@wjog.jp06-6633-7400

Outcome results